Navigation Links
CEL-SCI Takes Delivery of New Manufacturing Facility
Date:10/9/2008

VIENNA, Va., Oct. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM) announced today that it has taken delivery of the new manufacturing facility for its lead drug Multikine(R). This dedicated facility, located in the Baltimore area, will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug. The facility, which cost about $22 million to build, is state of the art and will soon be commercial ready. As it stands today, the facility can produce about $600 million worth of drug per year. Within one year it can be built out to product almost $2 billion worth of drug per year.

Geert Kersten, CEL-SCI's Chief Executive Officer said, "Multikine started with the idea that activating the immune system to fight cancer could be beneficial and successful, as long as you could activate the immune system before it was weakened by surgery, radiation and chemotherapy. Our clinical studies showed significant benefit to the cancer patients treated with Multikine. We are now in the home stretch. Having our own Multikine dedicated manufacturing facility gives us control and eliminates a great deal of risk from our product development. Our next step is to completely validate the facility and to bring it on line for manufacturing."

CEL-SCI is developing Multikine for approval as a first line indication in head and neck cancer. To that end, the Company's upcoming Phase III clinical trial is an 800 patient clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any conventional cancer treatmen
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Ground-Breaking Conference Takes on Abortion
9. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
10. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
11. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... 14 LI-COR Biosciences introduces a,new, novel protein ... Imaging system. The Odyssey Two-Color Protein Molecular Weight,Marker ... 800 nm channels of the,Odyssey System. The marker ... be used to visualize the progress of protein ...
... National Drug Control Policy to Moderate ... Bad Drugs, FRAZER, Pa., Oct. 14 ... embarking on a national educational,program designed to promote ... the importance of appropriate and responsible use of,prescription ...
... ProtoKinetix (OTC,Bulletin Board: PKTX), a biotech ... of patented anti-aging glycopeptides,(AAGPs(TM)), announced today that ... a division of National Financial Communications Corp.,(NFC), ... "ProtoKinetix, AAGP(TM) platform technology is ideal ...
Cached Biology Technology:LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker 2Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 2ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base 3
(Date:9/18/2014)... people are too stressed they are often grouchy, grumpy, ... Institute (BMI) at EPFL have just highlighted a fundamental ... and the loss of social skills and cognitive impairment. ... regulatory molecule in the brain. This was revealed by ... , Carmen Sandi,s team went to look for answers ...
(Date:9/18/2014)... Clownfish spend their entire lives nestling in the protective ... as babies they sometimes travel hundreds of kilometres across ... by reef fish has been predicted, this is the ... between distant populations has been observed. , Dr Steve ... at the University of Exeter, and colleagues from the ...
(Date:9/17/2014)... student have designed a device based on a shorebird,s ... dew., The device could provide water in drought-stricken areas ... Luo, professor in the Mechanical & Aerospace Engineering Department, ... of Engineering department, published "Bioinspired Plate-Based Fog Collectors" in ... Applied Materials & Interfaces journal. ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... 23andMe, the leading personal genetics company, announces the ... Neil Rothstein as Vice President Marketing, and Jonathan ... company,s executive leadership team. As ... the company,s corporate communications, media relations and investor ...
... Oct. 17, 2012 Rising crime rates and ... increase monitoring and introduce reliable border control systems. ... criminal identification and automated immigration at all entry ... adoption in the government vertical across Asia-Pacific. ...
... 24, 2012  Aware, Inc. (NASDAQ: AWRE ), ... assurance products, today reported financial results for its third ... our DSL service assurance hardware business have been reported ... the shutdown of that business during the third quarter. ...
Cached Biology News:23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 2Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 3Increased Focus on Security Bolsters Growth of Biometrics Market in Asia-Pacific, Finds Frost & Sullivan 4Aware, Inc. Reports Third Quarter 2012 Financial Results 2Aware, Inc. Reports Third Quarter 2012 Financial Results 3Aware, Inc. Reports Third Quarter 2012 Financial Results 4Aware, Inc. Reports Third Quarter 2012 Financial Results 5Aware, Inc. Reports Third Quarter 2012 Financial Results 6
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
... has a long and outstanding history ... Several years ago we became aware ... was being modified to inject Xenopus ... redesigning the microdispenser to eliminate any ...
...
... designed for sequencing inserts cloned into M13/pUC-based ... T3 RNA polymerase promoters, or lambda gt10 ... a concentration of 0.1 µg/µl in water. ... sequencing reactions using SequiTherm™ EXCEL™ II DNA ...
Biology Products: